Mu-Sen Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mu-Sen Liu has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Binzhang Shen
Tango Therapeutics, Boston, Massachusetts
19 shared publications - Chengyin Min
Tango Therapeutics (United States) 2 Boston, MA
19 shared publications - Douglas A. Whittington
Tango Therapeutics (United States) 2 Boston, MA
19 shared publications - Jannik Nørgaard Andersen
Tango Therapeutics, Boston, Massachusetts
19 shared publications - Patrick McCarren
Tango Therapeutics (United States) 2 Boston, MA
19 shared publications - William D. Mallender
Tango Therapeutics (United States) 2 Boston, MA
19 shared publications
Latest Publications
- Open Access
- 12 September 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (11)
Genetic and biochemical screens identify MGAT1 as a druggable glycosyltransferase target in STK11-mutant lung cancer
- 12 September 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (11)
Open AccessGenetic and biochemical screens identify MGAT1 as a druggable glycosyltransferase target in STK11-mutant lung cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
CRISPRi system does not reduce viability of BRCA mutant cells using an intron-targeting control guide RNA (sgITC). Representative image (A) and quantification (B) of colony formation assay (treatment day 14) in MDA-MB-436 (BRCA1 mutant) cells engineered to express a DOX-inducible CRISPRi guide RNA targeting an intron (sgITC). Knockdown was validated by Western blot (representative image in C, quantification in D). FC, fold-change.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
CRISPRi system does not reduce viability of BRCA mutant cells using an intron-targeting control guide RNA (sgITC). Representative image (A) and quantification (B) of colony formation assay (treatment day 14) in MDA-MB-436 (BRCA1 mutant) cells engineered to express a DOX-inducible CRISPRi guide RNA targeting an intron (sgITC). Knockdown was validated by Western blot (representative image in C, quantification in D). FC, fold-change.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
LIG1 inactivation is lethal in BRCA1-mutant MDA-MB-436 cells, and is rescued by exogenous expression of wild-type BRCA1. A) Representative colony formation assay (treatment day 14) using DOX-inducible shRNA against LIG1, PLK1 (pan-lethal control), or a control sequence in MDA-MB-436 cells stably infected with cDNA encoding wild-type BRCA1 or a control vector. B) Model validation with Western blotting. C) Western blots assessing LIG1 protein level at assay endpoint.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
LIG1 inactivation is lethal in BRCA1-mutant MDA-MB-436 cells, and is rescued by exogenous expression of wild-type BRCA1. A) Representative colony formation assay (treatment day 14) using DOX-inducible shRNA against LIG1, PLK1 (pan-lethal control), or a control sequence in MDA-MB-436 cells stably infected with cDNA encoding wild-type BRCA1 or a control vector. B) Model validation with Western blotting. C) Western blots assessing LIG1 protein level at assay endpoint.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Perturbation of LIG1 induces proportional PAR accumulation in BRCA1-mutated cells in immunofluorescence and in-cell western assay formats. A) In-cell Western blotting of PAR on treatment day 4 in MDA-MB-436 cells engineered to express a DOX-inducible LIG1 cDNA with endogenous LIG1 knockout. B) Model validation with Western blotting. C) Quantification of relative NAD+ as deduced by total NAD (NADt)/NADH ratio normalized to +DOX condition (t-test sgLIG1 +DOX vs. -DOX p < 0.0001).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Perturbation of LIG1 induces proportional PAR accumulation in BRCA1-mutated cells in immunofluorescence and in-cell western assay formats. A) In-cell Western blotting of PAR on treatment day 4 in MDA-MB-436 cells engineered to express a DOX-inducible LIG1 cDNA with endogenous LIG1 knockout. B) Model validation with Western blotting. C) Quantification of relative NAD+ as deduced by total NAD (NADt)/NADH ratio normalized to +DOX condition (t-test sgLIG1 +DOX vs. -DOX p < 0.0001).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Withdrawal of Doxycycline leads to LIG1 depletion that is sustained through the study. Image (A) and quantification (B) of western blotting data from tumors of immunodeficient mice grafted with MDA-MB-436 cells engineered to express a DOX-inducible CRISPR-resistant LIG1 cDNA with endogenous LIG1 knockout. Samples depicted are from endpoint (day 29 post-grouping).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Withdrawal of Doxycycline leads to LIG1 depletion that is sustained through the study. Image (A) and quantification (B) of western blotting data from tumors of immunodeficient mice grafted with MDA-MB-436 cells engineered to express a DOX-inducible CRISPR-resistant LIG1 cDNA with endogenous LIG1 knockout. Samples depicted are from endpoint (day 29 post-grouping).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Quantification of western blots for dTAG-mediated LIG1 degradation. MDA-MB-436 cells were engineered to express a CRISPR-resistant LIG1 cDNA fused to either the FKBP12mut (dTAG) degron (degradable) (A) or the FKBP12wt degron (non-degradable) (B), with knockout of endogenous LIG1. Cells were then treated for 4 days with vehicle (DMSO) or the indicated doses of the VHL-targeting PROTAC dTAGv1 and then subject to immunoblotting for LIG1, HA tag, and a loading control. FC, fold-change.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Quantification of western blots for dTAG-mediated LIG1 degradation. MDA-MB-436 cells were engineered to express a CRISPR-resistant LIG1 cDNA fused to either the FKBP12mut (dTAG) degron (degradable) (A) or the FKBP12wt degron (non-degradable) (B), with knockout of endogenous LIG1. Cells were then treated for 4 days with vehicle (DMSO) or the indicated doses of the VHL-targeting PROTAC dTAGv1 and then subject to immunoblotting for LIG1, HA tag, and a loading control. FC, fold-change.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
LIG1 inactivation is lethal in HRD+ BRCA1/2 wild-type HCC1806 cells. A) Representative colony formation assay (treatment day 11) using DOX-inducible shRNA against LIG1, PLK1 (pan-lethal control), or a control sequence in HCC1806 cells. B) Western blots assessing LIG1 protein level in the models from (A) (treatment day 4).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
LIG1 inactivation is lethal in HRD+ BRCA1/2 wild-type HCC1806 cells. A) Representative colony formation assay (treatment day 11) using DOX-inducible shRNA against LIG1, PLK1 (pan-lethal control), or a control sequence in HCC1806 cells. B) Western blots assessing LIG1 protein level in the models from (A) (treatment day 4).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Cell lines with damaging mutations in BRCA2 are dependent on LIG1. A) Analysis of DepMap data (28) comparing LIG1 dependence of cell lines with damaging mutations in BRCA2 vs. BRCA2 wild-type cell lines. ***p=0.0004 unpaired t-test. B,C) Representative image (B) and quantification (C) of colony formation assay in DLD1 wild-type (WT) and BRCA2-/- cells transfected with siRNAs targeting the LIG1 gene or a control sequence. D,E) Representative image (D) and quantification (E) of Western blot assessing LIG1 knockdown at endpoint for the colony formation assay in (B).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Cell lines with damaging mutations in BRCA2 are dependent on LIG1. A) Analysis of DepMap data (28) comparing LIG1 dependence of cell lines with damaging mutations in BRCA2 vs. BRCA2 wild-type cell lines. ***p=0.0004 unpaired t-test. B,C) Representative image (B) and quantification (C) of colony formation assay in DLD1 wild-type (WT) and BRCA2-/- cells transfected with siRNAs targeting the LIG1 gene or a control sequence. D,E) Representative image (D) and quantification (E) of Western blot assessing LIG1 knockdown at endpoint for the colony formation assay in (B).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Synthetic lethality approaches in BRCA1/2-mutated cancers have focused on PARP inhibitors, which are subject to high rates of innate or acquired resistance in patients. In this study, we used CRISPR/Cas9-based screening to identify DNA ligase I (LIG1) as a novel target for synthetic lethality in BRCA1-mutated cancers. Publicly available data supported LIG1 hyperdependence of BRCA1 mutant cells across a variety of breast and ovarian cancer cell lines. We used CRISPRn, CRISPRi, RNAi, and protein degradation to confirm the lethal effect of LIG1 inactivation at the DNA, RNA, and protein level in BRCA1 mutant cells in vitro. LIG1 inactivation resulted in viability loss across multiple BRCA1-mutated cell lines, whereas no effect was observed in BRCA1/2 wild-type cell lines, demonstrating target selectivity for the BRCA1 mutant context. On-target nature of the phenotype was demonstrated through rescue of viability with exogenous wild-type LIG1 cDNA. Next, we demonstrated a concentration-dependent relationship of LIG1 protein expression and BRCA1 mutant cell viability using a titratable, degradable LIG1 fusion protein. BRCA1 mutant viability required LIG1 catalytic activity, as catalytically dead mutant LIG1K568A failed to rescue viability loss caused by endogenous LIG1 depletion. LIG1 perturbation produced proportional increases in PAR staining in BRCA1 mutant cells, indicating a mechanism consistent with the function of LIG1 in sealing ssDNA nicks. Finally, we confirmed LIG1 hyperdependence in vivo using a xenograft model in which LIG1 loss resulted in tumor stasis in all mice. Our cumulative findings demonstrate that LIG1 is a promising synthetic lethal target for development in patients with BRCA1-mutant cancers.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Synthetic lethality approaches in BRCA1/2-mutated cancers have focused on PARP inhibitors, which are subject to high rates of innate or acquired resistance in patients. In this study, we used CRISPR/Cas9-based screening to identify DNA ligase I (LIG1) as a novel target for synthetic lethality in BRCA1-mutated cancers. Publicly available data supported LIG1 hyperdependence of BRCA1 mutant cells across a variety of breast and ovarian cancer cell lines. We used CRISPRn, CRISPRi, RNAi, and protein degradation to confirm the lethal effect of LIG1 inactivation at the DNA, RNA, and protein level in BRCA1 mutant cells in vitro. LIG1 inactivation resulted in viability loss across multiple BRCA1-mutated cell lines, whereas no effect was observed in BRCA1/2 wild-type cell lines, demonstrating target selectivity for the BRCA1 mutant context. On-target nature of the phenotype was demonstrated through rescue of viability with exogenous wild-type LIG1 cDNA. Next, we demonstrated a concentration-dependent relationship of LIG1 protein expression and BRCA1 mutant cell viability using a titratable, degradable LIG1 fusion protein. BRCA1 mutant viability required LIG1 catalytic activity, as catalytically dead mutant LIG1K568A failed to rescue viability loss caused by endogenous LIG1 depletion. LIG1 perturbation produced proportional increases in PAR staining in BRCA1 mutant cells, indicating a mechanism consistent with the function of LIG1 in sealing ssDNA nicks. Finally, we confirmed LIG1 hyperdependence in vivo using a xenograft model in which LIG1 loss resulted in tumor stasis in all mice. Our cumulative findings demonstrate that LIG1 is a promising synthetic lethal target for development in patients with BRCA1-mutant cancers.